Macromolecular systems for chemotherapy and magnetic resonance Imaging

Advanced Drug Delivery Reviews

Volumn 18, Issue 2, 1996, Pages 219-267

  Matthews, Susan E ^a   Pouton, Colin W ^a   Threadgill, Michael D ^a  

^a University of Bath   (United Kingdom)

Author keywords

Biodistribution; Chelating agent; Lysosomal degradation; Paramagnetic ion; Poly(amino) acid; Poly(ethylene glycol); Polysaccharide; Tumor targeting; Watersoluble polyacrylate

Indexed keywords

AGENTS; CHARACTERIZATION; DRUG THERAPY; IONS; MAGNETIC RESONANCE IMAGING; MOLECULAR WEIGHT; ONCOLOGY; PHARMACOKINETICS; POLYACRYLATES; POLYSACCHARIDES;

BIODISTRIBUTION; CHELATING AGENTS; CHEMOTHERAPY; ENDOCYTOSIS; ENDOTHELIAL PERMEABILITY; LYMPHATIC DRAINAGE; LYSOSONAL DEGRATION; PARAMAGNETIC ION; POLYAMINO ACID; TUMOR TARGETING;

MACROMOLECULES;

ANTINEOPLASTIC AGENT; CHELATING AGENT; CONTRAST MEDIUM; DAUNORUBICIN; DEXTRAN; DIAGNOSTIC AGENT; EDETIC ACID; GADOLINIUM PENTETATE MEGLUMINE; INULIN; LIPOSOME; MACROGOL; METAL COMPLEX; MITOMYCIN C; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PENTETIC ACID; POLYACRYLIC ACID; POLYAMINOACID; POLYGLUTAMIC ACID; POLYHYDROXYETHYLASPARTAMIDE; POLYHYDROXYETHYLGLUTAMINE; POLYLYSINE; POLYMER; POLYSACCHARIDE; PRODRUG; PROTOPORPHYRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DRUG DEGRADATION; DRUG PENETRATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; ENDOCYTOSIS; HUMAN; INTERNALIZATION; LYSOSOME; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; TISSUE DISTRIBUTION;

EID: 0030031245     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00098-R     Document Type: Review

References (201)

1. Bader, H., Ringsdorf, H. and Schmidt, B. (1984) Water soluble polymers in medicine. Angew. Makromol. Chem. 123/124, 457-485.
2. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 51, 135-153.
3. De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P. and Van Hoof. (1974) Lysosomotropic agents. Biochem. Pharmacol. 23, 2495-2531.
4. Sezaki, H. and Hashida, M.(1983) Macromolecular-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1, 1-38.
5. Larsen, C. (1989) Dextran prodrugs - structure and stability in relation to therapeutic activity. Adv. Drug Deliv. Rev. 3, 103-154.
6. Duncan, R., Cable, H.C., Rejmanova, P., Kopecek, J. and Lloyd, J.B. (1984) Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys. Acta 799, 1-8.
7. Duncan, R., Kopecek, J., Rejmanova, P. and Lloyd, J.B. (1983) Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta 755, 518-521.
8. Shen, W.-C., Ryser, H.J.P. and LaManna, L. (1985) Disulfide spacer between methotrexate and poly(D-lysine). J. Biol. Chem. 260, 10905-10908.
9. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392.
10. Mego, J.L. and McQueen, J.D. (1965) The uptake of labeled proteins by particulate fractions of tumor and normal tissue after injection into mice. Cancer Res. 25, 865-869.
11. Seymour, L.W. (1992) Passive tumour targeting of soluble macromolecules and drug conjugates. CRC Crit. Rev. Ther. Drug Carrier Syst. 9, 135-187.
12. Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210.
13. Joyner, W.L. and Kern, D.F. (1990) Microvascular permeability to macromolecules and its dynamic modulation. Adv. Drug Deliv. Rev. 4, 319-342.
14. Folkman, J. and Klagsbrun, M. (1987) Angiogenic factors. Science 235, 442-447.
15. Senger, D.R., Galli, S.S., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S. and Dvorak, H.F. (1983) Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
16. Maeda, H., Seymour, L.W. and Miyamoto, Y. (1992) Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 3, 351-362.
17. Dvorak, H.F., Senger, D.R, Dvorak, A.M., Harvey, V.S. and McDonagh, J. (1985) Regulation of extracellular coagulation by microvascular permeability. Science 227, 1059-1061.
18. Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6, 181-202.
19. Jain, R.K. (1987) Transport of macromolecules in the tumour interstitium: a review. Cancer Res. 47, 3039-3051.
20. Lloyd, J.B. (1989) Explorations in cell biology and pharmacology using synthetic polymers. Angew. Makromol. Chem. 166/167, 191-200.
21. Pratten, M.K. and Lloyd, J.B. (1986) Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim. Biophys. Acta 881, 307-313.
22. Besterman, J.M. and Low, R.B. (1983) Endocytosis: a review of mechanisms and plasma membrane dynamics. Biochem. J. 210, 1-13.
23. 2 mice. Br. J. Cancer 63, 859-866.
24. Duncan, R., Rejmanova, P., Kopecek, J. and Lloyd, J.B.(1981) Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim. Biophys. Acta 678, 143-150.
25. Lloyd, J.B. and Williams, K.E. (1984) Non-specific adsorptive pinocytosis. Biochem. Soc. Trans. 12, 527-528.
26. Fallen, R.J. and Schwartz, A.L. (1989) Receptor-mediated delivery of drugs to hepatocytes. Adv. Drug Deliv. Rev. 4, 49-63.
27. Lloyd, J.B., Pratten, M.K., Duncan, R., Kooistra, T. and Cartlidge, S.A. (1984) Substrate selection and processing in endocytosis. Biochem. Soc. Trans. 12, 977-978.
28. Duncan, R., Starling, D., Rypacek, F., Drobnik, J. and Lloyd, J.B. (1982) Pinocytosis of poly(α,β-(N-2-hydroxyethyl)-DL-aspartamide and tyramine derivatives by rat visceral yolk sacs cultured in vitro. Biochim. Biophys. Acta, 1982, 717, 248-254.
29. Duncan, R., Cable, H.C., Rypacek, F., Drobnik, J. and Lloyd, J.B. (1985) Characterisation of the adsorptive pinocytic capture of a polyaspartamide modified by the incorporation of tyramine residues. Biochim. Biophys. Acta 840, 291-293.
30. Duncan, R., Cable, H.C., Rypacek, F., Drobnik, J. and Lloyd, J.B. (1984) Enhancement of adsorptive pinocytosis of a polyaspartaraide modified by the incorporation of tyramine residues. Biochem. Soc. Trans. 12, 1064.
31. Pratten, M.K., Lloyd, J.B., Hörpel, G. and Ringsdorf, H. (1985) Micelle-forming block copolymers: pinocytosis by macrophages and interaction with model membranes. Makromol. Chem.186, 725-733.
32. Pratten, M.K., Cable, H.C., Ringsdorf, H. and Lloyd, J.B. (1982) Adsorptive pinocytosis of polycationic copolymers of vinylpyrrolidone with vinylamine by rat yolk sac and rat peritoneal macrophages. Biochim. Biophys. Acta, 719, 424-430.
33. Seymour, L.W. (1994) Soluble polymers for lectin-mediated drug targeting. Adv. Drug Deliv. Rev. 14, 89-111.
34. Vansteenkiste, S., Schacht, E., Duncan, R., Seymour, L., Pawluczyk, I. and Baldwin, R. (1991) Fate of glycosylated dextrans after in vivo administration. J. Control. Release 16, 91-100.
35. Wedge, S.R., Duncan, R. and Kopeckova, P.(1991) Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration to the rat. Br. J. Cancer 63, 546-549.
36. Duncan, R., Kopeckova, P., Strohalm, J., Hume, I.C., Lloyd, J.B. and Kopecek, J. (1988) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 57, 147-156.
37. Monsigny, M., Roche, A.-C., Midoux, P. and Mayer, R. (1994) Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes. Adv. Drug Deliv. Rev. 14, 1-24.
38. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I., Cable, H.C., Pohl, J., Lloyd, J.B. and Kopecek, J. (1987) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer 55, 165-174.
39. Duncan, R., Hume, I.C., Kopeckova, P., Ulbrich, K., Strohalm, J. and Kopecek, J. (1989) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. III. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Control. Release 10, 51-63.
40. Domurado, M., Domurado, D., Vansteenkiste, S., De Marre, A. and Schacht, E. (1995) Glucose oxidase as a tool to study in vivo the interaction of glycosylated polymers with the mannose receptors of macrophages. J. Control. Release 33, 115-123.
41. Seymour, L.W., Duncan, R., Kopeckova, P. and Kopecek, J. (1987) Potential of sugar residues attached to N-(2-hydroxypropyl)methacrylamide copolymers as targeting groups for the selective delivery of drugs. J. Bioact. Compatible Polym. 2, 97-119.
42. Flanagan, P.A., Kopecekova, P., Kopecek, J. and Duncan, R. (1989) Evaluation of N-(2-hydroxypropyl)methacrylamide copolymers as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody conjugates. Biochim. Biophys. Acta 993, 83-91.
43. Gros, L., Ringsdorf, H. and Schupp, H. (1981) Polymeric antitumour agents on a molecular and on a cellular level? Angew. Chem. Int. Ed. Engl. 20, 305-325.
44. Duncan, R. and Spreafico, F. (1994) Polymer conjugates; pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 27, 290-306.
45. Wagner, E., Curiel, D. and Gotten, M. (1994) Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug. Deliv. Rev. 14, 113-135.
46. 125I]daunomycin. J. Control. Release 10, 37-49.
47. Rihova, B., Jegorov, A., Strohalm, J., Matha, V., Rossmann, P., Fornusek, L. and Ulbrich, K. (1992) Antibody-targeted cyclosporin A. J. Control. Release 19, 25-40.
48. 6 toward human hepatocarcinoma cell line (PLC/PRF/S) targeted with galactosamine and to mouse splenocytes targeted with anti-Thy 1.2 antibodies. J. Control. Release 25, 71-87.
49. Rihova, B., Vetvicka, V., Strohalm, J., Ulbrich, K. and Kopecek, J. (1989) Action of polymeric prodrugs based on N-(2-hydroxypropyl)methacrylamide copolymers. I. Suppression of the antibody response and proliferation of mouse splenocytes in vitro. J. Control. Release 9, 21-32.
50. Kopecek, J., Rihova, B. and Krinik, N.L. (1991) Targetable photoactivatable polymeric drugs. J. Control. Release 16, 137-144.
51. Seymour, L.W., Flanagan, P.A., Al-Shamkhani, A., Subr, V., Ulbrich, K., Cassidy, J. and Duncan, R. (1991) Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Selective Cancer Ther. 7, 59-73.
52. Shen, W.-C., Du, X., Feener, E.P. and Ryser, H.J.P. (1989) The intracellular release of methotrexate from a synthetic drug carrier system targetd to Fc receptor-bearing cells. J. Control. Release 10, 89-96.
53. O'Hare, K.B., Duncan, R., Strohalm, J., Ulbrich, K. and Kopeckova, P. (1993) Polymeric drug carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. J. Drug Targeting 1, 217-229.
54. Gantz, I., Miwa, H., Konda, Y., Shimto, Y., Tashiro, T., Watson, S.J., DelValle, J. and Yamada, T. (1993) Molecular cloning, expression and gene localisation of a fourth melanocortin receptor. J. Biol. Chem. 268, 15174-15179.
55. Roselli-Rehfuss, L., Mountjoy, K.G., Robbins, L.S., Mortrud, M.T., Low, M.J., Tatro, J.B., Entwistle, M.L., Simerley, R.B. and Cone, R.D. (1993) Identification of a receptor for γ-melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl. Acad. Sci. USA 90, 8856-8860.
56. Bird, S.J. and Lloyd, J.B. (1990) Evidence for a dipeptide porter in the lysosome membrane. Biochim. Biophys. Acta 1024, 267-270.
57. Rejmanova, P., Kopecek, J., Pohl, J., Baudys, M. and Kostka, V. (1983) Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184, 2009-2020.
58. Shen, W.-C. and Ryser, H.J.P. (1981) Cis-aconityl spacer between daunomycin and macromolecular carriers; a model of pH-sensitive likage releasing drug from a lysosomotropic agent. Biochem. Biophys. Res. Commun. 102, 1048-1054.
59. Daussin, F., Boschetti, E., Delmotte, F. and Monsigny, M. (1988) p-Benzylthiocarbamoyl-aspartyl-daunorubicin-substituted polytrisacryl. A new drug acid-labile arm-carrier conjugate. Eur. J. Biochem. 176, 625-628.
60. Shen, W.-C. (1990) Acid-sensitive dissociation between polylysine and histamine modified poly(glutamate) as a model for drug-releasing carriers in endosomes. Biochim. Biophys. Acta 1034, 122-124.
61. Bonfils, E., Depierreux, C., Midoux, P., Thuong, N.T., Monsigny, M. and Roche, A.C. (1992) Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. Nucleic Acids Res. 20, 4621-4629.
62. Kopecek, K., Cifkova, I., Rejmanova, P., Strohalm, J., Obereigner, B. and Ulbrich, K (1981) Polymers containing enzymatically degradable bonds. 4. Preliminary experiments in vivo. Makromol. Chem. 182, 2941-2949.
63. Kopecek, K. Rejmanova, P. and Chytry, V (1981) Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalysed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chem. 182, 799-809.
64. Duncan, R., Cable, H.C., Lloyd, J.B., Rejmanova, P. and Kopecek, J. (1982) Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Rep. 2, 1041-1046.
65. Pato, J., Azori, M., Ulbrich, K. and Kopecek, J. (1984) Polymers containing enzymatically degradable bonds. 9. Chymotrypsin catalysed hydrolysis of a p-nitroanilide drug model bound via oligopeptides onto poly(vinylpyrrolidone co maleic anhydride). Makromol. Chem. 185, 231-237.
66. Ulbrich, K., Strohalm, J. and Kopecek, J. (1986) Poly(ethylene glycol)s containing enzymatically degradable bonds. Makromol. Chem. 187, 1131-1144.
67. Duncan, R., Lloyd, J.B. and Kopecek, J.(1980) Degradation of side chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal enzymes. Biochem. Biophys. Res. Commun. 94, 284-290.
68. Ulbrich, K., Zachaneva, E.I., Kopecek, J., Hume, I.C. and Duncan, R. (1987) Polymer-bound derivatives of sarcolysin and their antitumour activities against mouse and human leukaemia in vitro. Makromol. Chem. 188, 2497-2509.
69. Rejmanova, P., Kopecek, J., Duncan, R. and Lloyd, J.B. (1985) Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials 6, 45-48.
70. Subr, V., Strohalm, J., Ulbrich, K., Duncan, R. and Hume, I.C. (1992) Polymers containing enzymatically degradable bonds. XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo. J. Control. Release 18, 123-132.
71. Seymour, L.W., Ulbrich, K., Strohalm, J., Kopecek, J. and Duncan, R. (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39, 1125-1131.
72. Duncan, R., Hume, I.C., Yardley, H.J., Flanagan, P.A., Ulbrich, K., Subr, V. and Strohalm, J., (1991) Macromolecular prodrugs for use in targeted cancer chemotherapy; melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Control. Release 16, 121-136.
73. Duncan, R., Seymour, L.W., O'Hare, K.B., Flanagan, P., Wedge, S., Hume, I.C., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., Grandi, M., Ripamonti, M., Farao, M. and Surato, A. (1992) Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release 19, 331-346.
74. Seymour, L.W., Ulbrich, K., Steyger, P.S., Brereton, M., Subr, V., Strohalm, J. and Duncan, R. (1994) Tumour tropism and anti-cancer efficacy of polymer-bound doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636-641.
75. Hoes, C.J.T., Grootoonk, J., Duncan, R., Hume, I.C., Bhakoo, M., Bouma, J.M.W, and Feijen, J. (1993) Biological properties of adriamycin bound to biodegradable polymeric carriers. J. Control. Release 23, 37-54.
76. De Marre, A., Seymour, L.W. and Schacht, E. (1994) Evaluation of the hydrolytic and enzymatic stability of macromolecular mitomycin C derivatives. J. Control. Release 31, 89-97.
77. Subr, V., Kopecek, J., Pohl, J., Baudys, M. and Kostka, V. (1988) Cleavage of oligopeptide side chains in N-(2-hydroxypropyl)methacrylamide copolymers by mixtures of lysosomal enzymes. J. Control. Release 8, 133-140.
78. Trouet, A., Deprez-De Campeneere, D. and De Duve, C. (1972) Chemotherapy through lysosome with a DNA-daunomycin complex. Nat. New Biol. 239, 110-112.
79. Trouet, A., Masquelier, M., Baurain, R. and Deprez-De Campeneere, D. (1982) A covalent linkage between daunomycin and proteins that is stable in serum and reversable by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate; in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 79, 626-629.
80. Masquelier, M., Baurain, R. and Trouet, A. (1980) Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties and lysosomal digestion. J. Med. Chem. 23, 1166-1170.
81. Baurain, R., Masquelier, M., Deprez-De Campeneere, D. and Trouet, A. (1980) Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumour activity on L1210 leukemic cells in vitro and in vivo. J. Med. Chem. 23, 1171-1174.
82. Sezaki, H., Takakura, Y. and Hashida, M. (1989) Soluble macromolecular carriers for the delivery of antitumour drugs. Adv. Drug Deliv. Rev. 3, 247-266.
83. Schacht, E., Vercauteren, R. and Vansteenkiste, S. (1988) Some aspects of the application of dextran in prodrug design. J. Bioact. Compatible Polym. 3, 72-80.
84. Fujita, T., Yasuda, Y., Takakura, Y., Hashida, M. and Sezaki, H. (1990) Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules; uricase-dextran conjugates. J. Control. Release 11, 149-156.
85. Schacht, E. (1987) Polysaccharide macromolecules as drug carriers. In: L. Ilium and S.S. Davis (Eds), Polymers in Controlled Delivery, Wright, Bristol, UK, pp. 131-151.
86. Vercauteren, R., Schacht, E. and Duncan, R. (1992) Effect of chemical modification of dextran on the degradation by rat liver lysosomal enzymes. J. Bioact. Compatible Polym. 7, 346-357.
87. Crepon, B., Jozefonvicz, J., Chytry, V., Rihova, B. and Kopecek, J. (1991) Enzymatic degradation and immunogenic properties of derivatised dextrans. Biomaterials 12, 550-554.
88. Chiu, H.-C., Konak, C., Kopeckova, P. and Kopecek, J. (1994) Enzymatic degradation of poly(ethylene glycol) modified dextrans. J. Bioact. Compatible Polym. 19, 388-410.
89. Rihova, B. and Riha, I. (1983) Immunological problems of polymer-bound drugs. CRC Crit. Rev. Ther. Drug Carrier Syst. 1, 311-375.
90. Takakura, Y., Matsumoto, S., Hashida, M. and Sezaki, H. (1989) Physicochemical properties and antitumour activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control. Release 10, 97-105.
91. Schacht, E., Ruys, L., Vermeersch, J., Remon, J.P. and Duncan, R. (1985) Use of polysaccharides as drug carriers. Dextran and inulin derivatives of procainamide. Ann. NY Acad. Sci. 446, 199-212
92. Vermeersch, J. and Schacht, E. (1985) Synthesis of succinoylated inulin and applications as a carrier for procainamide. Bull. Soc. Chim. Belg. 94, 287-291.
93. Vermeersch, J. and Schacht, E. (1986) Synthesis and characterisation of inulin monosaccharides. Makromol. Chem. 187, 125-131.
94. Hoes, C.J.T., Potman, W., van Heeswijk, W.A.R., Mud, J., de Grooth, B.C., Greve, J. and Feijen, J. (1985) Optimization of macromolecular prodrugs of the anti-tumor antibiotic adriamycin. J. Control. Release 2, 205-213.
95. van Heeswijk, W.A.R., Hoes, C.J.T., Stoffer, T., Eenink, M.J.D., Potman, W. and Feijen, J. (1985) The synthesis and charcterisation of polypeptide adriamycin conjugates and its complexes with adriamycin. Part 1. J. Control. Release 1, 301-315.
96. Schechter, B., Neumann, A., Wilchek, M. and Arnon, R. (1989) Soluble polymers as carriers of cis-platinum. J. Control. Release 10, 75-87.
97. Rosowsky, A. and Wright, J.E. (1989) N-[[2-(Trimethylsilyl)ethoxy]carbonyl] derivatives of tri-L-lysine and tetra-L-lysine as potential intermediates in block polymer synthesis of macromolecular drug conjugates. J. Org. Chem. 54, 5551-5558.
98. Choksakulnimitr. S., Masuda, S., Tokuda, H., Takakura, Y. and Hashida, M. (1995) In vitro cytotoxicity of macromolecules in different cell culture systems. J. Control. Release 34, 233-241.
99. Vermeersch, H. and Remon, J.P. (1994) Immunogenicity of poly-D-lysine, a potential polymeric drug carrier. J. Control. Release 32, 225-229.
100. Negre, E., Chance, M.L., Hanboula, S.Y., Monsigny, M., Roche, A.-C., Mayer, R.M and Hommel, M. (1992) Antileishmanial drug targeting through glycosylated polymers specifically internalised by macrophage membrane lectins. Antimicrob. Agents Chemother. 36, 2228-2232.
101. Midoux, P., Negre, E., Roche, A.-C., Mayer, R., Monsigny, M., Balzarini, J., De Clercq, E., Mayer, E., Ghaffer, A. and Gangemi, J.D. (1990) Drug targeting: anti-HSV-1 activity of mannosylated polymer-bound 9-(2-phosponylmethoxyethyl) adenine. Biochem. Biophys. Res. Commun.167, 1044-1049.
102. Hudecz, F., Gaal, D., Kurucz, I., Lanyi, A., Kovacs, A.L., Mezo, G., Rajnavolgyi, E. and Szekerke, M. (1992) Carrier design: cytotoxicity and immunogenicity of synthetic branched polypeptides with poly(L-lysine) backbone. J. Control. Release 19, 231-244.
103. De Marre, A. and Schacht, E. (1992) Preparation of 4-nitrophenol carborate esters of poly[N-5-(2-hydroxyethyl)-L-glutamine] and coupling with bioactive agents. Makromol. Chem. 193, 3023-3030.
104. De Marre, A., Soyez, H. and Schacht, E. (1994) Synthesis of mitomycin C derivatives. J. Control. Release 32, 129-137.
105. Pytela, J., Saudek, V., Drobnik and J., Rypacek, F. (1989) Poly(N-hydroxyalkylglutamine)s. IV. Enzymatic degradation of N-(2-hydroxyethyl)-L-glutamine homopolymer and copolymers. J. Control. Release 10, 17-25.
106. 5-hydroxyethyl-L-glutamine-co-L-glutamic acid copolymer in rats. J. Bioact. Compatible Polym. 8, 51-68.
107. Giammona, G., Carlisi, B. and Palazzo, S. (1987) Reaction of α,β-(poly(N-hydroxyethyl)-DL-aspartamide with derivatives of carboxylic acids. J. Polym. Sci. Polym. Chem., 1987, 25, 2813-2818.
108. Giammona, G., Puglisi, G., Cavallaro, G., Spadaro, A. and Pitarresi, G. (1995) Chemical stability and bioavailability of acyclovir coupled to a,β-(poly(N-hydroxyethyl)-DL-aspartamide. J. Control. Release 33, 261-271.
109. Kopecek, J. (1977) Reactive copolymers of N-(2-hydroxypropyl)methacrylamide with N-methacryloated derivatives of L-leucine and L-phenylalanine. Makromol. Chem. 178, 2169-2183.
110. Lääne, A., Chytry, V., Haga, M., Sikk, P., Aaviksaar, A. and Kopecek, J. (1981) Covalent attachment of chymotrypsin to poly[N-(2-hydroxypropyl)methacrylamide]. Coll. Czech. Chem. Commun. 46, 1466-1473.
111. Lääne, A., Haga, M., Aaviksaar, A., Chytry, V. and Kopecek, J. (1983) Activation of poly[N-(2-hydroxypropyl)methacrylamide] for the binding of bioactive molecules. Makromol. Chem. 184, 1339-1344.
112. Chytry, V. and Kopecek, J. (1983) Activation of poly[N-(2-hydroxypropyl)methacrylamide] for the binding of bioactive molecules. 1. Activation with 4-nitrophenol chloroformate. Makromol. Chem. 184, 1345-1353.
113. Rejmanova, P., Labsky, J. and Kopecek, J. (1977) Aminolysis of monomeric and polymeric 4-nitrophenol esters of N-methacryloylamino acids. Makromol. Chem. 178, 2159-2168.
114. Scahcht, E., Ruys, L., Goethals, E., Gyselinck, P., Van Severen, R. and Braeckmann, P. (1981) Drug polymer combinations. III. Synthesis of the methacrylamide derivative of procainamide and its homopolymer. J. Pharm. Belg. 36, 113-117.
115. Rihova, B., Bilej, M., Vetvicka, V., Ulbrich, K., Strohalm, J., Kopecek, J. and Duncan, R. (1989) Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Biomaterials 10, 335-342.
116. Cartlidge, S.A., Duncan, R., Lloyd, J.B., KopeckovaRejmanova, P. and Kopecek, J. (1987) Soluble cross-linked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 3. Targeting by incorporation of galactosamine residues. Effect of route of administration. J. Control. Release 4, 265-278.
117. Rejmanova, P., Obereigner, B. and Kopecek, J.(1981) Polymers containing enzymatically degradable bonds. 2. Poly[N-(2-hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable by chymotrypsin. Makromol. Chem., 1981, 182, 1899-1915.
118. Ulbrich, K., Strohalm, J. and Kopecek, J. (1981) Polymers containing enzymatically degradable bonds. 3. Poly[N-(2-hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable by trypsin. Makromol. Chem. 182, 1917-1928.
119. Ulbrich, K., Zacharieva, E.I., Obereigner, B. and Kopecek, J. (1980) Polymers containing enzymatically degradable bonds. 5. Hydrophilic polymers degradable by papain. Biomaterials 1, 199-204.
120. Cartridge, S.A., Duncan, R., Lloyd, J.B., Kopeckova-Rejmanova, P. and Kopecek, J. (1987) Soluble cross-linked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 2. Effect of molecular weight on blood clearance and body distribution in the rat after intravenous administration. J. Control. Release 4, 253-264.
121. Kopecek, J. (1990) The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery. J. Control. Release 11, 279-290.
122. Rihova, B., Kopecek, J., Ulbrich, K., Popisil, M. and Mancal, P. (1984) Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 5, 143-148.
123. Flanagan, P.A., Strohalm, J., Ulbrich, K. and Duncan, R. (1993) Effect of pre-immunisation on the activity of polymer-doxorubicin against mouse L1210 leukaemia. J. Control. Release 26, 221-228.
124. Katre, N.V. (1993) The conjugation of proteins with polyethylene glycol and other polymers. Altering properties to enhance their therapeutic potential. Adv. Drug Deliv. Rev., 10, 91-114.
125. Yoshinga, K. and Harris, J.M. (1989) Effects of coupling chemistry on the activity of poly(ethylene glycol)-modified alkaline phosphatases J. Bioact. Compatible Polym. 4, 17-24.
126. Fuertges, F. and Abuchowski, A. (1990) The clinical efficacy of poly(ethylene glycol)-modified proteins. J. Control. Release 11, 139-148.
127. Loccufier, J., Cremmon, J., Vadorpe, J. and Schacht E. (1991) End group modification of α-hydroxy-ω-methoxypoly(oxyethylene) - facile methods for the introduction of a α-amino end group. Makromol. Chem. Rapid Commun. 12, 159-165.
128. Vansteenkiste, S., Schacht, E., Ranucci, E. and Ferruti, P. (1992) Synthesis of a new family of poly(amido amine)s carrying poly(oxyethylene) side chains. Makromol. Chem. 193, 937-943.
129. Shafer, S.G. and Harris, J.M.. (1986) Preparation of cyanuric chloride activated poly(ethylene glycol). J. Polym. Sci. Polym. Chem. 24, 375-378.
130. Nucci, M.L., Shorr, R. and Abuchowski, A. (1991) The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev. 6, 133-151.
131. Delgado, C., Francis, G.E. and Fisher, D.(1992) The uses and properties of PEG-linked proteins. CRC Crit. Rev. Ther. Drug Carrier Syst. 9, 249-304.
132. Zalipsky, S., Seltzer, R. and Menon-Rudolph, S. (1992) Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotech. Appl. Biochem. 15, 100-114.
133. Andrews, B.A., Head, D.M., Dunthorne, P. and Asenjo, J. A. (1990) PEG activation and ligand binding and the affinity partitioning of proteins in aqueous two-phase systems. Biotech. Tech. 4, 49-54.
134. Head, D.M., Andrews, B.A. and Asenjo, J.A. (1989) Epoxy-oxirane activation of PEG for protein ligand coupling. Biotech. Tech. 3, 27-32.
135. Nathan, A., Zalipsky, S., Ertel, S.I., Agathos, S.N., Yarmush, M.L and Kohn, J. (1993) Copolymers of lysine and polyethylene glycols; a new family of functionalized drug carriers. Bioconj. Chem. 4, 54-62.
136. Yokoyama, M., Okano, T., Sakurai, Y. and Kataoka, K. (1994) Improved synthesis of adriamycin-conjugated poly(ethyloxide)-poly(aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin. J. Control. Release 32, 269-277.
137. Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y. and Kataoka, K. (1994) Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J. Control. Release 29, 17-23.
138. Yokoyama, M., Miyauchi, M., Yamada, N., Okano, T., Sakurai, Y., Kataoka, K. and Inoue, S. (1990) Polymer micelles as novel drug carrier: adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J. Control. Release 11, 269-278.
139. Yokoyama, M. (1992) Block copolymers as drug carriers. CRC Crit. Rev. Ther. Drug Carrier Syst. 9, 213-248.
140. Yamoka, T., Tabata, Y. and Ikada, Y. (1984) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weight after intravenous administration into rats. J. Pharm. Sci. 83, 601-606.
141. Yokoyama, M., Inoue, S., Kataoka, K., Yui, N., Okano, T. and Sakurai, Y. (1989) Molecular design for missile drug: synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier. Makromol. Chem. 190, 2041-2054.
142. Ohya, Y., Kuroda, H. and Ouchi, T. (1994) Specific drug delivery using PEG/ADR conjugate and PEG/ ADR/saccharide conjugate. Proc. Int. Symp. Control. Release Bioact. Mater. 21, 666-667.
143. Lauffer, R.B. (1987) Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem. Rev. 87, 901-927.
144. Parker, D. (1994) Targeting metal complexes. Chem. Br. 818-822.
145. Watson, A.D., Rocklage, S.M. and Carvlin, M.J. (1991) Contrast agents. In: D.D. Stark and W.G. Bradley (Eds), Magnetic Resonance Imaging, Vol. 1, 2nd Edn, Mosby Year Book Inc., USA, pp. 372-437.
146. Mattrey, R.F. (1989) Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging. Am. J. Roentgenol. 152, 247-252.
147. Saini, S., Frankel, R.B., Stark, D.D. and Ferruci, J.T. (1988) Magnetsim: a primer and review. Am. J. Roentgenol. 150, 735-743.
148. Runge, V.M., Stewart, R.G., Clanton, J.A., Jones, M.M., Lukehart, C.M., Partain, C.L. and James, A.E. (1983) Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology 147, 788-791.
149. Runge, V.M., Clanton, J.A., Herzer, W.A., Gibbs, S.J., Price, A.C., Partain, C.L. and James, A.E. (1984) Intravascular contrast agents suitable for magnetic resonance imaging. Radiology 153, 171-176.
150. Feinberg, D.A., Crooks, L., Hoenninger, J., Arakawa, M. and Watts, J. (1984) Pulsatile blood velocity in human arteries displayed by magnetic resonance imaging. Radiology 153, 177-180.
151. Runge, V.M., Foster, M.A., Clanton, J.A., Jones, M.M., Lukehart, C.M., Hutchinson, J.M.S., Mallard, J.R., Smith, F.W., Partain, C.L. and James, A.E. (1984) Contrast enhancement of magnetic resonance imaging by chromium EDTA: an experimental study. Radiology 152, 123-126.
152. Brasch, R.C., Weinmann, H.-J. and Wesbey, G.E. (1984) Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complexes. Am. J. Roentgenol. 142, 625-630.
153. Carr, D.H., Brown, J., Bydder, G.M., Steiner, R.E., Weinmann, H.-J., Speck, U., Hall, A.S. and Young, I.R. (1984) Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. Am. J. Roentgenol. 143, 215-224.
154. Creasy, J.L., Price, R.R., Presbrey, T., Goins, D., Partain, C.L. and Kessler, R.M. (1990) Gadolinium-enhanced MR angiography. Radiology, 175, 280-283.
155. Brown, J.J. and Higgins, C.B. (1988) Myocardial paramagnetic contrast agents for MR imaging. Am. J. Roentgenol. 151, 865-872.
156. Pavone, P., Patrizio, G., Buoni, C., Tettamanti, E., Passariello, R., Musu, C., Tirone, P. and Felder, E. (1990) Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 176, 61-64.
157. Rummney, E., Ehrenheim, C., Gehl, H.B., Hamm, B., Laniado, M., Lodemann, K.P., Schmiedel, E., Steudel, A. and Vogl, T.G.(1991) Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumours. Invest. Radiol. 26, s142-s145.
158. Vittadini, G., Felder, E., Musu, C. and Tirone, P. (1990) Preclinical profile of Gd-BOPTA as a liver-specific MRI contrast agent. Invest. Radiol. 25, s59-s60.
159. Ni, Y., Marchal, G., Zhang, X., Van Hecke, P., Michiels, J., Yu, J., Rummeny, E., Lodemann, K.-P. and Baert, A.L.(1993) The uptake of manganese dipyridoxaldiphosphate by chemically induced hepatocellular carcinoma in rats. Invest. Radiol. 28, 520-528.
160. Bousequet, J.-C., Saini, S., Stark, D.D., Hahn, P.F., Nigam, M., Wittenberg, J. and Ferruci, J.T. (1988) Gd-DOTA; charcterisation of a new paramagnetic complex. Radiology 166, 693-698.
161. Ash, D. and Brown, S.B. (1989) Photodynamic therapy-achievements and prospects. Br. J. Cancer 60, 151-152.
162. Megnin, F., Faustino, P.J., Lyon, R.C., Lelkes, P.I. and Cohen, J.S. (1987) Studies on the mechanism of selective retention of porphyrins and metalloporphyrins by cancer cells. Biochim. Biophys. Acta 929, 173-181.
163. Patronas, N.J., Cohen, J.S., Knop, R.H., Dwyer, A.J., Colocher, D., Lundy, J., Mornex, F., Hambright, P., Sohn, M. and Myers, C.E. (1986) Metalloporphyrin contrast agents for magnetic resonance imaging of human tumours in mice. Cancer Treatment Rep. 70, 391-395.
164. Furmanski, P. and Longley, C. (1988) Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. Cancer Res. 48, 4604-4610.
165. Chen, C.-W., Cohen, J.S., Myers, C.E. and Sohn, M. (1984) Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett. 168, 70-74.
166. Jackson, L.S., Nelson, J,A., Case, T.A. and Burnham, B.F. (1985) Manganese protoporphyrin IX. A potential intravenous paramagnetic NMR contrast agent: preliminary communication. Invest. Radiol. 20, 226-229.
167. Hoehn-Berlage, M., Norris, D., Bockhorst, K., Ernestus, R.-I., Kloiber, O., Bonnekoh, P., Leibfritz, D. and Hossman, K.-A. (1992) Snapshot FLASH measurement of rat brain glioma: kinetics of the tumor enhancing contrast agent manganese(III) tetraphenylporphyrin sulfonate. Magn. Reson. Med. 27, 201-213.
168. 4. Invest. Radiol. 27, 536-542.
169. Greif, W.L., Buxton, R.B., Lauffer, R.B., Saini, S., Stark, D.D., Wedeen, V.J., Rosen, B.R. and Brady, T.J. (1985) Pulse sequence optimization for MR imaging using a paramagnetic hepatobiliary contrast agent. Radiology 157, 461-466.
170. Hindré, F., Le Plouzennec, M., De Certaines, J.D., Foultier, M.T., Patrice, T. and Simonneaux, G. (1993) Tetra-p-aminophenylporphyrin conjugated with Gd-DTPA: tumor specific contrast agent for MR imaging. J. Magn. Reson. Imaging 3, 59-65.
171. Foster, N., Woo, D.V., Kaltovich, F., Emrich, J. and Ljungquist, C. (1985) Delineation of a transplanted malignant melanoma with indium-111-labeled porphyrin. J. Nucl. Med. 26, 756-760.
172. Cavagna. F., Luchinat, C., Scozzafava, A. and Xia, Z.(1994) Polymetallic macromolecules are potential contrast agents of improved efficiency. Magn. Reson. Med. 31, 58-60.
173. Von Schulthess, G.K., Duewell, S., Jenny, H.-B., Wüthrich, R. and Peter, H.H. (1990) Polyethylene glycol-ferrioxamine. A new magnetic resonance contrast agent. Invest. Radiol. 25, s48.
174. Schmiedl, U., Ogan, M., Paajanen, H., Marotti, M., Crooks, L.E., Brito, A.C. and Brasch, R.C. (1987) Comparison of the contrast enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.OT. Radiology 162, 205-210.
175. Schmiedl, U., Sievers, R.E., Brasch, R.C., Wolfe, C.L., Chew, W.M., Ogan, M.D., Engeseth, H., Lipton, M.J. and Moseley, M.E. (1989) Acute myocardial ischaemia and reperfusion: MR imaging with albumin-Gd-DTPA. Radiology 170, 351-356.
176. Adam, G., Neuerburg, J., Spüntrup, E., Mühler, A., Scherer, K. and Günther, R.W. (1994) Dynamic contrast-enhanced MR imaging of the upper abdomen: enhancment properties of gadobutrol, gadolinium-DTPA-polylysine and gadolinium-DTPA-cascade polymers. Magn. Reson. Med. 32, 622-628.
177. Meyer, D., Schaeffer, M., Bouillot, A., Beauté, S. and Chambon, C. (1991) Paramagnetic dextrans as magnetic resonance contrast agents. Invest. Radiol. 25, s50-s52.
178. Wang, S.-C., Wikström, M.G., White, D.L., Klaveness, J., Holtz, R., Rongved, P., Moseley, M.E. and Brasch, R.C. (1990) Evaluation of Gd-DTPA-labeled dextran as an intramuscular MR contrast agent: imaging characteristics in normal rat tissues. Radiology 175, 483-488.
179. Wiener, B.C., Brechbiel, M.W., Brothers, H., Magin, R.L., Gansow, O.A., Tomalia, D.A. and Lauterbur, P,C. (1994) Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn. Reson. Med. 31, 1-8.
180. 40. Invest. Radiol. 26, s42-s45.
181. Spaltro, S.M. and Foster, N. (1990) Synthesis and characterisation of conjugates of poly(α-amino acids) and manganese(III) protoporphyrin IX as relaxaton enhancement agents for MRI. J. Appl. Polym. Sci., 1990, 41, 1235-1249.
182. Kellar, K.E., Spaltro, S.M. and Foster, N. (1990) Relaxation enhancement of water protons by manganese III porphyrins: influence of porphyrin aggregation. Macromolecules 23, 428-431.
183. Tilcock, C., Unger, E., Cullis, P. and MacDougall, P. (1989) Liposomal Gd-DTPA: preparation and charcterisation of relaxivity. Radiology 171, 77-80.
184. Seltzer, S.E.(1989) The role of liposomes in diagnostic imaging. Radiology 171, 19-21.
185. Tilcock, C., MacDougall, P., Unger, E., Cardenas, D. and Fajardo, L. (1990) The effect of lipid composition on the relaxivity of Gd-GTPA entrapped in lipid vesicles of defined size. Biochim. Biophys. Acta 1022, 181-186.
186. Unger, E., Tilcock, C., Ahkong, Q.F. and Fritz, T. (1990) Paramagnetic liposomes as magnetic resonance contrast agents. Invest. Radiol. 25, s65-s66.
187. Unger, E., Winokur, T., MacDougall, P., Rosenblum, J., Clair, M., Gatenby, R. and Tilcock, C. (1989) Hepatic metastases: liposomal Gd-DTPA-enhanced imaging. Radiology 171, 81-85.
188. Kabalka, G., Buonocore, E., Hubner, K., Moss, T., Norley, N. and Huang, L. (1987) Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology 163, 255-258.
189. Schwendener, R.A., Wüthrich, R., Duewell, S., Wehrli, E. and Von Schulthess, G.K. (1990) A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese, and iron-DTPA-stearate liposomes as organspecific contrast agents. Invest. Radiol. 25, 922-932.
190. Rongved, P., Lindberg, B. and Klaveness, J. (1991) Cross-linked degradable starch microspheres as carriers of paramagnetic contrast agents for magnetic resonance imaging: synthesis, degradation and relaxation properties. Carbohydr. Res. 214, 325-330.
191. Brasch, R.C., London, D.A., Wesbey, G.E., Tozer, T. N., Nitecki, D.E., Williams, D.W., Doemeny, J., Tuck, L.D. and Lalemand, D.P. (1983) Work in progress: nuclear magnetic resonance study of a paramagnetic nitroxide contrast agent for enhancement of renal structures in experimental animals. Radiology, 1983, 147, 773-779.
192. Saini, S., Stark, D.D., Hahn, P.F., Wittenberg, J., Brady, T.J. and Ferruci, J.T. (1987) Ferrite particles: a supraparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 162, 211-216.
193. Saini, S., Stark, D.D., Hahn. P.F., Bousquet, J.-C., Introcasso, J., Wittenberg, J., Brady, T.J. and Ferrucci, J.T. (1987) Ferrite particles: a supraparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 162, 217-222.
194. Hahn, P.F., Stark, D.D., Weissleder, R., Elizondo, G., Saini, S. and Ferruci, J.T. (1990) Clinical applications of supraparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 174, 361-366.
195. Stark, D.D., Weissleder, R., Eloizondo, G., Hahn, P.F., Saini, S., Todd, L.E., Wittenberg, J. and Ferruci. J.T. (1988) Supraparamagnetic iron oxide: clinical applications as s contrast agent for MR imaging of the liver. Radiology 168, 297-301.
196. Kent, T.A., Quast, M.J., Kaplan, B.J., Lifsey, R.S. and Eisenberg, H.M. (1990) Assessment of a supraparamagnetic iron oxide (AMI-25) as a brain contrast agent. Magn. Reson. Med. 13, 434-443.
197. Rozenman, Y., Zou, X. and Kantor, H.L. (1990) Cardiovascular MR imaging with iron oxide particles: utility of a supraparamagnetic contrast agent and the role of diffusion in signal loss. Radiology 175, 655-659.
198. Bulte, J.W.M., De Jonge, M.W.A., Kamman, R.L., Go, K.G., Zuiderveen, F., Blaauw, B., Oosterbaan, J.A., The, T. H. and De Leij, L. (1992) Dextran-magnetite particles: contrast enhanced MRI of blood-brain barrier disruption in a rat model. Magn. Reson. Med. 23, 215-223.
199. Widder, D.J., Greif, W.L., Widder, K.J., Edelmam, R.R. and Brady, T.J. (1987) Magnetite albumin microspheres: a new MR contrast material. Am. J. Roentgenol. 148, 399-404.
200. Weissleder, R., Elizondo, G., Wittenberg, J., Rabito, C.A., Bengele, H.H. and Josephson, L. (1990) Ultra-small supraparamagnetic iron oxide: characterisation of a new class of agents for MR imaging. Radiology 175, 489-493.
201. Weissleder, R., Elizondo, G., Wittenberg, J., Lee, A. S., Josephson, L. and Brady, T.J. (1990) Ultrasmall supraparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175, 494-498.